History
February 1999: Founding of tgcBIOMICS GmbH by Prof. Dr. Christoph von Eichel-Streiber and Prof. Dr. Trinad Chakraborty. The founding idea is based on a patent for the TGC method filed for in 1997 by the founders.
August 2000: Successful completion of the first financing round. SUPPORTA CAPITAL GROWTH, specialized in investments in medical technologies and pharmaceuticals is the lead investor. The three shareholders, Dr. von Eichel-Streiber, Dr. Chakraborty and Supporta Capital Growth Inc. are holding the total number of the company shares.
|
August 2000: The tbg (technology-Beteiligungs-Gesellschaft mbH of the Deutsche Ausgleichsbank, Germany) and the ISB (Investitions- und Strukturbank Rheinland-Pfalz) entered silent holdings with the three firms: WFT (Wagnisfinanzierungsgesellschaft für Technologieförderung in Rheinland-Pfalz mbH), FIB (Fonds für Innovation und Beschäftigung Rheinland-Pfalz Unternehmensbeteiligungsgesellschaft mbH); VcR (Venture-Capital Rheinhessen Unternehmensbeteiligungsgesellschaft mbH).
October 2000: Commencement of operative business. Dr. Christoph von Eichel-Streiber is appointed CEO of the company; Dr. Trinad Chakraborty is chair of the Advisory Board.
October 2001: Move to the offices and laboratories at BioPark-Mainz - creating optimal conditions for continued dynamic growth. At Biopark, tgcBIOMICS possesses all approvals under the German Infection Protection Act (Infektionsschutzgesetz) and Genetic Engineering Act (Gentechnikgesetz).
|
 |
|
August 2002: Use of bacterial gene carriers increases the transfection rate to 30% of cells in culture (over initial 5% of cells; evidence through FACS analysis of expression of reporter protein).
October 2002: Application for production permits for herd-specific vaccines from the state of Rhineland-Palatinate.
|
|
TGC Biomics GmbH, Carl-Zeiss-Str. 51, 55129 Mainz | Tel.+49(0)6131 62757-10 | mail@tgcbiomics.de
